Ascendis Pharma (NASDAQ:ASND) has filed a Clinical Trial Notification with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan seeking approval to initiate Phase 3 riGHt Trial of TransCon hGH (lonapegsomatropin), a long-acting prodrug of somatropin (hGH), for the treatment for pediatric growth hormone deficiency (GHD).
The 40-subject trial will evaluate and compare the annualized height velocity in prepubertal treatment naïve children with GHD, treated with weekly TransCon hGH to that of a commercially available daily hGH formulation, at 52 weeks.
https://seekingalpha.com/news/3616681-ascendis-pharma-files-for-late-stage-study-transcon-in-japan
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.